- 1 Randomized trial to compare acceptability of Magnesium Sulphate administration for
- 2 preeclampsia and eclampsia: Springfusor pump versus standard of care
- 3
- 4 Authors
- 5 Sam Ononge^{1#}, Annettee Nakimuli¹, Josephat Byamugisha¹, Moses Adroma¹, Paul Kiondo¹,
- 6 Thomas Easterling², Hillary Bracken³
- ⁷ ¹Department of Obstetrics and Gynaecology Makerere University College of Health Sciences
- 8 ²University of Washington Seattle Washington USA
- 9 ³Gynuity Health Projects NY USA
- ¹Sam Ononge, Department of Obstetrics & Gynaecology, Makerere University College of Health
- 11 Sciences, Kampala, Uganda
- ¹Annettee Nakimuli, Department of Obstetrics & Gynaecology, Makerere University College of
- 13 Health Sciences, Kampala, Uganda
- ¹Josephat Byamugisha, Department of Obstetrics & Gynaecology, Makerere University College
- 15 of Health Sciences, Kampala, Uganda
- ¹⁶ ¹Moses Adroma, Department of Obstetrics & Gynaecology, Makerere University College of
- 17 Health Sciences, Kampala, Uganda
- ¹Paul Kiondo, Department of Obstetrics & Gynaecology,
- 19 Makerere University College of Health Sciences, Kampala, Uganda
- 20 ²Thomas Easterling, University of Washington Seattle Washington USA
- ³Hillary Bracken, Gynuity Health Projects (GHP), 220 East 42nd Street, New York, NY 10017
- 22 USA
- 23
- 24
- 4 25 # Corresponding author: email ononge2006@yahoo.com
- 26

27 Abstract

Introduction: In low-resource settings, magnesium sulphate (MgSO₄) for preeclampsia is
 administered majorly through an injection into the gluteal muscles 4-hourly for 24 hours. The
 repeated injections are very painful and may lead to infection, abscess formation and reduced
 compliancy.

- 32 **Objective:** To determine the acceptability of Springfusor® pump for the administration of
- 33 Magnesium Sulphate in preeclampsia and eclampsia.
- 34 **Design**: Randomized Open Label Clinical Trial

Method: Study was conducted at Kawempe National Referral Hospital. Eligible women had 35 systolic blood pressure of >140mmHg and or diastolic blood pressure >90mmHg, proteinuria 36 >+1, and physician's decision to start on MgSO₄. Four-hundred-ninety-six participants were 37 randomized to Springfusor® pump group or control (standard of care) administration of MgSO₄. 38 39 Intervention group had loading dose (4gm of 50% MgSO₄ intravenously over 20 minutes) and maintenance therapy (1gm of 50% MgSO₄ intravenously per hour for 24 hours) administered 40 using the Springfusor \mathbb{R} . The control group received a loading dose of 4gm of 20% MgSO₄ IV 41 42 over 15-20 minutes, followed by 10gm of 50% MgSO₄ intramuscular (5gm in each buttock) and maintenance dose of 5gm of 50% MgSO₄ was administered IM every 4 hours for 24 hours. Both 43 arms received the rest of the care for preeclampsia/eclampsia as per the hospital guidelines. 44 Acceptability of method of administration was assessed using a Likert scale (1-5; 1 and 2: 45 acceptable and 3-5: unacceptable). Pain at site of MgSO₄ administration was assessed using 46 Visual Analogue Scale 1-7, (1 minimal pain and 7 worst pain). Comparisons were assessed with 47

48 X-square and Students' t-test.

- 49 **Results:** Baseline characteristics were similar in both arms. Intervention arm was; more
- 50 acceptable than the standard of care arm, (94.9% vs70.3%; p<0.001), had lower pain score
- 51 $(2.2\pm1.3 \text{ vs. } 4.1\pm1.6; \text{ p} < 0.001)$ and fewer side effects. Maternal mortality was comparable
- 52 between groups (0.8% in intervention arm vs 1.2% in the IM arm).
- 53 TRIAL REGISTRATION: Trial No PACTR201712002887266 (https://pactr.samrc.ac.za/)

54

56

57 Introduction

58	Preeclampsia is a multisystem disorder that presents with a raised blood pressure and proteinuria in
59	pregnancy [1]. Globally, preeclampsia complicates approximately 2-8% of the pregnancies [2]. The
60	presence of convulsions with preeclampsia indicates eclampsia. Preeclampsia and eclampsia are
61	life-threatening for both the mother and the fetus[3], and they are among the leading causes of
62	maternal deaths and disability worldwide, especially in the low resource setting[4]. The World
63	Health Organization (WHO) estimates that, 16% of the maternal deaths in low resource settings
64	are due to PE/E [5]. Magnesium Sulphate (MgSO ₄) is the drug of choice for prevention and
65	treatment of eclampsia [5]. It is administered parenterally by intravenous (IV) and or
66	intramuscular (IM) routes. The IV therapy is commonly administered following the Zuspan
67	regimen that requires an initial loading dose of 4 gm of magnesium sulphate over 15-20
68	minutesover 15-20 minutes (mins), followed by 1-2 gm hourly maintenance dose continuing for
69	24 hours after the loading dose or the last eclamptic fit [6]. Zuspan regimen is best delivered by
70	electronic infusion pumps. These electronic pumps are expensive and require electricity or
71	battery to run, making them less appropriate in low resource settings. In many low resource
72	settings, MgSO4 administration follows the Pritchard regimen. The regimen is particularly
73	complex and requires both the IV and IM administration of MgSO ₄ . The loading dose of 4 gm is
74	often delivered using an IV-push, in which clinicians slowly injects magnesium sulphate with a
75	syringe over 15-20 mins. This is immediately followed by IM injection of 10 gm of magnesium
76	sulphate into the gluteal muscles (5 gm on each buttock). The maintenance dose of 5 gm IM
77	injection is administered every 4 hours for 24 hours. These repeated IM injections are painful,
78	and can increase the risk of abscess development. Because of pain associated with the IM

79 injection, some providers do not administer maintenance therapy and patients too may 80 discontinue the maintenance dose for the same reason. In addition, the Pritchard regimen requires different dilutions for IV and IM doses, and different doses for loading, and maintenance 81 doses. This regimen requires a 20% dilution of magnesium sulphate for the IV loading dose, 82 83 which necessitates the health providers to calculate the quantity of sterile water to add to the magnesium sulphate solution. In most settings, health providers do not encounter eclampsia very 84 often; and when they do, trying to remember the complex regimen is challenging. 85 In low resources settings that cannot afford electronic infusion pumps, there was a need to test 86 alternative devices that can effectively and safely deliver MgSO₄ at cheaper cost, and 87 acceptable to the patient and health provider. The Springfusor® pump and flow control tube 88 (FCT) designed by Go Medical Industries Pty Ltd based in Australia [7], is a promising 89 alternative to Pritchard method of administering MgSO₄, and is designed to simplify 90 91 continuous IV infusions. The Springfusor pump does not require electricity and it is reusable. The Springfusor is powered by the potential energy stored within a spring at the heart of the 92 device. The spring is compressed by the action of loading the Springfusor with the compatible 93 94 syringe and FCT. The spring provides a constant force to the barrel of the loaded syringe. The flow rate is controlled by the FCT which offers consistent resistance to produce a steady flow. 95 The FCT is a fine bore tube designed to provide a metered constant flow for IV infusion. FCTs 96 has easy fitting to the patient's cannula. The FCT exist in a variety of flow rates which enables 97 the user to attain the desired output for exact IV delivery needs. For this study we used two 98 varieties of FCT; the loading dose and maintenance dose. While the Springfusor can be reused 99 indefinitely on different patients, the FCT must be replaced after each use. 100

101 The Springfusor syringe infusion pump is a low cost, non-sterile, reusable pump that requires 102 no external power source. It is simple to use and setup, and requires only minimal training to 103 load and operate. It is lightweight, portable and therefore does not limit the mobility of the 104 patient.

The Springfusor has been used to administer MgSO₄ in the treatment of severe preeclampsia in 105 106 India[8] [9]. In India, Mundle and colleagues compared the manually administered IV loading dose followed by maintenance therapy given by IM route of administration via a syringe, to a 107 loading dose and maintenance therapy given through IV infusion administered by a Springfusor 108 109 device. Though there were no difference in maternal and neonatal morbidity, the Springfusor had few side effects[9]. Later, Easterling et al compared the Springfusor administration of continuous 110 IV infusion of magnesium sulphate and 2 hourly IV boluses, the clinical findings were not 111 different in the two groups[8]. Earlier in 1994, Freebairn et al in Australia compared the 112 Spingfusor infusion device to intermittent boluses on administration of muscle relaxant. They 113 were able to show that Springfusor provided a more constant level of paralysis compared to 114 intermittent bolus administration [10]. The objective of this study was to assess the acceptability 115 and safety of Springfusor pump for intravenous delivery of magnesium sulphate for the treatment 116 of preeclampsia and eclampsia. 117

118 Methods

The trial protocol is submitted as a supplementary file (S2). The study was randomized open label clinical trial conducted at Kawempe national referral and teaching hospital in Kampala district Uganda. The hospital is a government public facility and its Maternal Fetal Unit admits and delivers approximately 2100 pregnant women per month. From the facility records, 7% of the admissions are preeclamptic/eclamptic women. The women with preeclampsia and eclampsia

are managed by cadres of health workers ranging from senior consultant obstetricians to medicalofficers, while the midwives administer the medication and nursing care.

126 The study included women with age of 15 years and above, with a pregnancy of 20+ weeks of

127 gestation or had childbirth within 24 hours, presenting with preeclampsia and eclampsia i.e.,

have a raised blood pressure (systolic of \geq 140 mmHg and/or diastolic \geq 90mmHg), proteinuria

129 $\geq 1+$. We excluded women who had received MgSO₄ 24 hours prior to admission, or had known

allergy to MgSO₄ and known elevated serum creatinine (>1.2 mg/dl) before enrolment.

131 Intervention: Women in the intervention arm (Springfusor® group) had the loading and

maintenance therapy of MgSO₄ using IV infusion administered using a Springfusor® infusion

pump. The loading dose was 4 gm of 50% MgSO₄ in 10 ml syringe administered over 20 mins.

134 The infusion rate was determined by the flow control tubing calibrated to deliver 10 ml of saline

over 5 mins (this system was demonstrated to deliver 4gm of 50% MgSO4 in 20 mins)[9]. The

maintenance dose of 4 gm of 50% MgSO₄ in 8 ml was administered over 4 hours and infusion

rate was determined by a second flow control tubing calibrated to deliver 10 ml of saline over 60

mins (this system was demonstrated to deliver 4gm of 50% MgSO4 in 4 hours)[9]. The 4-gm

dose of $MgSO_4$ was repeated every 4 hours for 24 hours.

Women in the control arm (standard of care) had $MgSO_4$ administered according to the standard

hospital practice. The loading dose of 4 gm of 20% MgSO₄ in 20 ml syringe was administered

using an IV infusion over 15-20 mins. This was immediately followed by IM injection of 10 gm

¹⁴³ of 50% MgSO₄ mixed with 1 ml of lignocaine into the gluteal muscles (5 gm on each buttock).

144 This was followed by maintenance dose of 5 gm IM injection, administered every 4 hourly for

145 24 hours.

146 Study procedure:

147	Between March and September 2019, women admitted at Kawempe hospital maternal fetal unit
148	were screened and enrolled into the study if they meet the inclusion criteria. The study team
149	obtained a written informed consent from the participant or from the relative if the mother was
150	eclamptic. Those with eclampsia provided individual written consent when they regained their
151	consciousness. Both arms received the care as per national guidelines which included
152	management of high blood pressure using antihypertensives, laboratory investigations (urine
153	analysis, complete blood count, renal function tests and liver function tests),
154	prevention/treatment of fits and delivery as planned by the attending physicians. Upon
155	enrolment, study participants were randomized to intervention or standard of care arms. The
156	prevention and treatment of fits were started as per hospital guidelines. The time it took to
157	administer the loading and maintenance doses in both arms were measured in mins by study
158	nurse using a stop clock. The time was measured from the loading of the MgSO ₄ into syringe to
159	completion of administration of the medicine in the syringe. For this paper we report the duration
160	in mins it took to administer the loading dose and the second maintenance dose.
161	The study participants' respiratory rates were monitored by the study midwives every 5 mins
162	during the loading dose for 30 mins and hourly during the 24 hours maintenance dose
163	administration. In addition, urine output and tendon reflexes were monitored hourly and
164	documented in the source documents. The side effects of MgSO ₄ like nausea, vomiting, flushing
165	of the skin, muscle weakness, confusion and drowsiness were reported 4 hourly and were
166	captured in questionnaire. The study participants were followed till discharge from the hospital
167	and pregnancy outcomes were extracted from the participants' records or charts.

168	The primary outcome was acceptability of the method of MgSO ₄ administration assessed using
169	Likert scale (1-5; 1: acceptable and 5: unacceptable), administered after the last maintenance
170	dose. The method of MgSO ₄ administration was regarded acceptable if participant rated it 1 or 2,
171	and was unacceptable if participant scored it 3 or more. The secondary outcomes were 1) the
172	level of pain experienced during administration of MgSO ₄ and this was assessed using a visual
173	analogue scale 1-7. The least (one) representing no pain and maximum (7) representing the worst
174	pain imaginable, 2) proportion of complications in two arms measure as proportion of
175	preeclamptic women who developed any one of the following; MgSO4 toxicity, abnormal liver
176	and renal function test as reported by the laboratory report, an infection at the injection as
177	reported by the clinician or a maternal deaths; 3) discontinuation rate was assessed as study
178	participants who did not complete the recommended doses of MgSO ₄ in 24 hour period.
179	Participants who discontinued the method of administration by choice, due to side effects or by
180	health workers decision were counted in each group, and; 4) reliability of Springfusor® pump in
181	the delivery of MgSO ₄ measured as time taken by the device to deliver the MgSO ₄ as per the
182	clinical recommendations.

183 Sample size, randomisation and statistical analysis

Based on the 31% acceptability of MgSO₄ administration using the Pritchard regimen (IM maintenance) in the Mundle et al trial[9], we calculated that we needed a sample size of 219 participants in each arm to give 90% power to detect 50% difference between the Springfusor arm and standard of care, with alpha of 0.05. With approximately 10% non-response, we needed 241 women in each arm.

189 Randomization was performed by a biostatistician not involved in the clinical trial who

190 developed the allocation sequence using an online computer random number generator in block

sizes of 4 and 6. The allocation sequence was concealed from the research team enrolling and
screening participant in serially numbered sealed opaque envelopes (concealed allocation)
containing the randomization group. After the research nurse had obtained the consent, she
opened the next envelope to determine the group assignment only after the participant is
enrolled, completed all the baseline assessment and it is time to allocate the intervention.
Because of the nature of the study, it was difficult to blind the implementation of the allocation
and measurement of the outcome.

Descriptive statistics were used to summarize baseline characteristics of study participants and 198 199 assess if randomization was successful. Acceptability and safety data were evaluated using intention-to-treat (ITT) analysis. The primary outcome (acceptability of administration of 200 MgSO₄ using Springfusor) was assessed using a Likert scale ranging from one (very acceptable) 201 to five (very unacceptable). The method of MgSO₄ administration was regarded acceptable if 202 203 participant rated 1 or 2 on the Likert scale. It is not acceptable if the rating was three and above. 204 Women who discontinue the method of administration by choice or due to side effects were considered in group of the unacceptable. The acceptability was compared in the two groups 205 using chi-square. Secondary outcomes (complications of preeclampsia and its management and 206 207 discontinuation rates) were compared using chi-square. While the level of pain was compared using means. The reliability of the Springfusor to administer MgSO₄ in the prescribed time was 208 209 assessed for the loading period and the maintenance period.

210 Ethical considerations

Approval for this research was provided by the Makerere University School of Medicine Research and
Ethics Committee (REC Ref 2018- 015) and the Uganda National Council for Science and Technology
(HS 2365). Study participants provided written informed consent. The trial was registered with Pan

214	African Clinical Trails PACTR201712002887266. The results are reported in accordance with the
215	CONSORT statement for randomized control trials[11] and checklist is provided as supporting file

216

217 **Results**

- 218 Participants flow: Eligible participants were recruited from March to August 2019.
- Approximately, ten thousand (9828) women admitted at the maternal fetal unit of Kawempe
- 220 national referral hospital during the study period were screened for eligibility (Fig. 1). A total of
- 496 eligible participants were randomized to intervention or standard of care. The loss-to-follow-
- 222 up was similar in both arms. The 5 referrals to other facilities were for renal consultations to rule
- 223 out possible acute kidney injury and Mulago Women Specialized Hospital to decongested
- 224 Kawempe hospital when it was overloaded with patients.

225 Baseline characteristics

Table 1 shows the baseline characteristics of the women enrolled in the control and interventions

- arms. The baseline data established that randomization of the two arms were similar for almost
- all variables except for presenting as a postpartum and multiple pregnancy. The differences in
- the 2 variables were not statistically significant. More than two thirds of participants were
- 230 referrals from lower facilities
- Table 1 Demographic and clinical characteristics of the study participants

Particulars		Standard of care (Pritchard) arm N=248 (%)	Springfusor arm N=248 (%)
Age in years			
	Mean (SD)	27.2 (5.5)	26.5 (5.6)
	Range	17 - 42	16 -45
Gravidity n (%)			
	1	83 (33.5)	94 (37.9)
	2	41 (16.7)	39 (15.7)

3	37 (15.1)	44 (17.7)
4	30 (12.1)	29 (12.0)
5+	44 (18.0)	35 (11.1)
Average gravida; mean (SD)	2.7 (1.7)	2.5 (1.7)
Enrolled postpartum (given birth)	13 (5.3)	7 (2.8)
n (%)		
Gestation age at enrollment n (%)		
20-33	74 (29.8)	61 (24.6)
34-37	78 (31.5)	94 (37.9)
38+	79 (31.9)	79 (31.9)
Unknown/missing/postpartum	17 (6.9)	14 (5.6)
Average gestation age in weeks at	34.4 (4.8)	34.8 (4.6)
enrolment; mean (SD)		
Gestation age range (weeks)	20 - 43	20 - 43
Number of ANC visits (%)		
None	10 (4.0)	8 (3.2)
1-3	145 (58.5)	142 (57.3)
4+	93 (37.5)	98 (39.5)
Average number of ANC visits;	3.0 (1.3)	3.2 (1.3)
mean (SD)		
Multiple pregnancy* (%)	21 (8.5)	14 (5.8)
Admitted as n (%)		
Referral in	179 (72.2)	172 (70.1)
Self-referral (Walk in)	23 (9.3)	34 (13.7)
Antenatal clinic at study site	46 (18.5)	42 (16.9)
Systolic BP at enrolment mmHg		
Mean (SD)	168.8 (22.4)	167.0 (21.0)
Range	126 - 237	130 - 270
≥160 mmHg (%)	145 (58.5)	151 (60.9)
Diastolic BP at enrolment mmHg		
Mean	111.5 (14.6)	112 (13.2)
Range	78 - 173	90 -162
≥110 mmHg (%)	129 (52.0)	142 (57.3)
Enrolled as Eclamptic (%)	14 (5.6)	11 (4.4)

232

Table 2 shows the laboratory parameters of the study participants enrolled into the control and
intervention arms. The baseline laboratory parameters were similar in the two with the exception
of low level of platelets and elevated serum creatinine in the intervention arm.

Table 2. Laboratory characteristics of the participants enrolled into the study

Particulars	Standard of care	Springfusor n=248 (%)
	N=248 (%)	
Low platelets (<100x10 ³ /µmoll)	20 (8.1)	29 (11.7)
Elevated alanine transaminase	46 (18.5)	40 (16.1)
(>31µmol/L)		
Elevated aspartate transaminase	70 (28.2)	69 (27.8)
(>32µmol/L)		
Raised bilirubin (>3.4µmol/L)	87 (35.1)	80 (32.2)
Elevated serum creatinine	20 (8.1)	38 (15.3)
$(\geq 1.2 \text{mg/dL})^*$		

- *Almost all the results were available for the attending physicians after the prevention and
- treatment of fits with magnesium sulphate was initiated or completed. None of the participants
- with elevated serum creatinine was excluded from the study.
- 240 The duration of MgSO₄ administration of loading dose was longer in the standard of care than in
- 241 Springfusor arm (table 3). Few women in both groups discontinued MgSO₄ (did not complete the
- recommended 24-hour doses) and the rates were similar (5.3% vs 5.0% p=0.862).
- Table 3. Drug administration and pain score registered by study participants

Particulars	Standard of care arm	Springfusor arm	pvalue
Average duration in mins of loading	25.8 (8.3)	21.1 (5.8)	P<0.001
dose magnesium administration (sd)			
Duration of administering the 2nd	2.8 (3.5)	236.3 (40.2)	N/A*
Maintenance (2 nd 4 hrs) in mins (sd)			
Discontinued MgSO4 administration	13 (5.3)	12 (5.0)	P=0.862
before 24 hours (%)			
Reasons for discontinuation of			
MgSO ₄			
Doctor's advice	7	7	
Patients request	4	4	
Referred to another facility before	2	1	
completion			
Pain score after administration of			
MgSO ₄ : 1(minimal), 7 (worst)			
1	11 (4.5)	71 (29.3)	
2	31 (12.6)	97 (40.1)	
3	48 (19.5)	38 (15.7)	
4	42 (17.1)	6 (2.5)	
5	55 (22.4)	14 (5.8)	
6	28 (11.4)	5 (2.1)	
7	21 (8.5)	4 (1.7)	
missing	10 (4.1)	7 (2.9)	

*Not provided statistic, will be misinterpreted and provides no meaning.

- As shown in table 4, almost all women in the intervention group found Springfusor
- administration of $MgSO_4$ acceptable (95%) compared to the standard of care (70%) and this was
- a statistically significant (chi 49.7 p<0.001). The women in the standard of care arm had a higher
- mean pain score than the intervention arm (standard of care: $4.1(\pm 1.6)$; Springfusor: $2.2(\pm 1.3)$
- 249 mean difference 1.9, CI: 1.8-3.0 p<0.001). More women in the intervention arm would
- recommend Springfusor method of administration of MgSO₄ to a friend compared to standard of
- care (96% vs 61%). Similarly, almost all women in the intervention arm would use the
- 252 Springfusor for magnesium administration when they have raised blood pressure in the next
- pregnancy compared to control arm who would Pritchard method (96.5% vs 66%).

Outcome	Control group (SOC) N=236(%)	Intervention group (Springfusor) N=235(%)		p-value
Primary outcome				
Acceptable ≤ 2 score on Likert scale (%)	166 (70.3)	224 (95.3)		< 0.001
Secondary outcomes				
Discontinuation; Not completed the 24 hrs (%)	13 (5.5)	12 (5.1)		0.862
Mean pain score during administration (sd)	4.1 (1.6)	2.2 (1.3)	Mean diff 1.9 (CI: 1.8 - 3.0)	< 0.001
Would recommend method of administration of MgSO ₄ to friend (%).	145 (61.4)	226 (96.2)		<0.001
Would use it in future she got raised BP in next pregnancy	155 (65.7)	225 (95.7)		<0.001

Table 4. Acceptability of MgSO₄ administration using Springfusor compared to standard of care

- 256 The side effects like flushes, nausea, vomiting, drowsiness, and diplopia were more in the
- standard of care than in springfusor (table 5). However, the adverse events like respiratory
- depression, depressed patellar reflex and cardiac arrest were very few and were comparable in
- the two arms

Particulars	Total (N=487)	Standard of care $(n=245)$	Springfusor (n= 242)
Flushes	373 (76.8)	201 (80.0)	172 (71.4)
Nausea	120 (24.7)	70 (28.6)	50 (20.8)
Vomiting	56 (11.5)	33 (13.5)	23 (9.5)
Headache	107 (22.0)	52 (21.2)	55 (22.8)
Drowsiness	164 (33.7)	97 (39.6)	67 (27.8)
Diplopia	16 (3.3)	7 (2.9)	9 (3.7)
Burning/warm sensation at site of injection	136 (28.0)	68 (27.8)	68 (28.2)
Respiratory depression <16 breath/min	2 (0.5)	1 (0.5)	1 (0.5)
Depressed patellar reflexes	1 (0.5)	1 (0.5)	0 (0.0)
Cardiac arrest	2 (0.5)	1 (0.5)	1 (0.5)

Table 5. Adverse and Side effects experienced during the 24 hours of drug administration

261

Approximately 6% of the participants were discharged from the hospital while still pregnant

after the blood pressures were controlled (table 6). Though outcomes of pregnancy were

comparable in both arms, more women were delivered by caesarean section in the Springfusor

arm than SOC. There were approximately 3% of the participants were referred to renal physician

for specialized care (including dialysis) and follow up. Unfortunately, there were 5 maternal

267 deaths in the whole study.

268 Table 6. Pregnancy outcome of the study participants

Characteristics	Total (%)	Standard of care	Intervention (%)
		(%)	
Discharged while still pregnant	28 (5.8)	18 (7.4)	10 (4.1)
Mode of delivery (n=458			
Caesarean	201 (43.9)	80 (35.2)	121 (52.4)
Vaginal	257 (56.1)	147 (64.8)	110 (47.6)
Outcome of the delivery			
(fetus)n=488			
Alive	398 (81.6)	195 (80.9)	203 (82.5)
Still births	84 (17.2)	43 (17.8)	41 (16.7)
missing	6 (1.2)	3 (1.2)	3 (1.2)
Weight of the baby			
<2500 gm	244 (50.5)	126 (52.3)	118 (48.8)
≥2500 gm	239 (49.5)	115 (47.7)	124 (51.2)
Referred to Nephrology hospital for	14 (2.9)	8 (3.3)	6 (2.5)
further renal care n=487			
Maternal death	5 (1.0)	3 (1.2)	2 (0.8)
No convulsion after loading dose	0	0	0

269

270 **Discussion**

271 The definitive treatment of preeclampsia is the delivery of the fetus and placenta. However,

before and after delivery of the baby and placenta, the goal of management is to control the

blood pressure to normal range and minimize the development of complications like eclampsia.

274 MgSO₄ is the anticonvulsant for eclampsia prophylaxis and treatment[12]. MgSO₄ therapy could

be given by continuous IV infusion (Zuspan) [6] or by administering an IV bolus and IM doses

for the loading dose followed by IM injections every 4 hours (Pritchard) used [13]. In low

277 resource settings due to unavailability of the electronic pumps, the Pritchard regimen is the

standard of care. The loading dose of 4gm of MgSO₄ is often delivered via an IV-push over 15-

279 20 mins. This process is challenging for the provider and difficult in a busy ward, and is

associated with inconsistent flow rates. If administered faster than the recommended 15-20 mins,

the IV-push may lead to increased pain, nausea, vomiting and flushing. Meanwhile the repeated

IM injections that follow the loading dose are associated with pain, hot flushes, somnolence, andsometimes abscess formation at the site of injection.

284 We assessed the acceptability and safety of Springfusor pump for intravenous delivery of MgSO₄ 285 for prophylaxis and treatment of eclampsia among women admitted at Kawempe national referral hospital. Acceptability of intravenous administration of MgSO₄ using Springfusor was 286 287 higher compared to Pritchard regimen (standard of care). The level of acceptability of intravenous administration of MgSO₄ using Springfusor was comparable to study by Mundle et 288 al in India that found that it was 97%[9]. The low acceptability associated with standard of care 289 290 is most likely due to pain that follows IM injection. Literature shows that the anxiety and fear associated with pain following IM injection reduces the acceptability of treatment to the patients 291 [14, 15]. With the four-hourly frequency of IM injection of MgSO₄ for prophylaxis and treatment 292 of preeclampsia and eclampsia in standard of care, injection site pain is an important concern and 293 294 local guidelines propose an addition of local anesthetic agent (Lignocaine) into the drug. Despite 295 the addition of 1 ml of lignocaine into every IM injection of MgSO₄, our study findings showed that participants on the standard of care experienced higher pain score than women who received 296 drug through intravenous administered through the Springfusor pump. 297

Majority (96%) of the participants in intervention arm responded that they would recommend IV magnesium sulfate administered using Springfusor to other patients compared to standard of care (61%). In addition, almost all participants in intervention arm (97%) compared to two thirds (66%) in standard of care would use MgSO₄ administered using Springfusor in future pregnancy if she gets preeclampsia. Literature reports that, when the safety and efficacy of two injection routes are equivalent, health care providers should consider more about patient preference because it will ensure optimal treatment adherence and ultimately improve patients experience or

satisfaction[16, 17]. In our study findings showed that no women developed a fit after enrolment, 305 indicating that both routes and dosing prevented and control the convulsions adequately. 306 307 Over all, the discontinuation rate was low (5.1%) and there was no difference in the two arms. 308 The low rates of discontinuation could be because this assessment was among participants that participated in research study environment which has ample opportunities for questions, 309 310 comments, and explanation of the process. In the real world, it is unlikely that this level of support will be available. Slightly more than half (56%) of the discontinuation were due to 311 312 physician on duty recommendation. The other reasons for discontinuation were due to participants request, and three patients referred to seek treatment in another facility. 313 The Springfusor® pump and flow control tube (FCT) is an encouraging alternative to repeated 314 315 IM administration of MgSO₄, designed to make simpler, the continuous IV infusions. It does not require electricity and it is reusable. The Springfusor is powered by the potential energy stored 316 within a spring at the heart of the device (Fig. 2) suitable for low resource settings. The FCT 317 exist in a variety of flow rates which enables the user to attain the desired output for exact IV 318 delivery needs. For this study we used two varieties of FCT as shown in the figure 2; the loading 319 dose and maintenance dose. The Springfusor syringe infusion pump is a low-cost technology that 320 requires only minimal training to load and operate. Being lightweight, and with a neck strap, it 321 does not limit the mobility of the patient (Fig. 3). 322 323 Thes study had some limitations. Firstly, the delay in accessing the laboratory work of the 324 participants, resulted in some participants who should be excluded based on serum creatinine,

enrolled into the study. The standard of care at the facility does not wait for laboratory results

before starting MgSO₄ prophylaxis. We operated within the hospital guidelines. Fortunately, no

327 participant experienced MgSO₄ toxicity. Secondly, we could not blind the study to the

- 328 participants and providers and might have influenced the reporting of the outcomes. The nature
- of the study could not enable blinding of the study.

330 Conclusion

- Acceptance of prescribed therapy is key for adherences and to clinical outcomes, and the effect is
- particularly critical for treatment that require repeated injections like MgSO₄ for preeclampsia
- and eclampsia. Pain associated with intramuscular injection (standard of care) was less with the
- intravenous infusion (Springfusor®) than with intramuscular administration. In addition, the
- intravenous administration was preferred to standard of care with women endorsing a greater
- likelihood to use it in next pregnancy or recommend it to a friend.
- 337 Acknowledgement
- 338 The authors are grateful to Kawempe National Referral Hospital administration and staff for support in
- 339 study implementation, data collectors for the great work done and the participants who gave in their time
- 340 to participate in the study.

341 **References**

- Report of the National High Blood Pressure Education Program Working Group on High Blood
 Pressure in Pregnancy. American journal of obstetrics and gynecology. 2000;183(1):S1-S22. PubMed
 PMID: 10920346.
- 2. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology.

346 2009;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010. PubMed PMID: 19464502.

- Mousa A, Mandili RL, Aljahdali M, Gari S, Khaimi S, Alahdal S, et al. Maternal and Fetal Outcomes
 of Preeclampsia With and Without Severe Features in King Abdulaziz University Hospital, Jeddah, Saudi
 Arabia: A Retrospective Study. Cureus. 2022;14(11):e31013. Epub 2022/12/08. doi:
- 350 10.7759/cureus.31013. PubMed PMID: 36475125; PubMed Central PMCID: PMCPMC9717715.
- 4. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal
- death: a WHO systematic analysis. The Lancet Global health. 2014;2(6):e323-33. Epub 2014/08/12. doi:
 10.1016/S2214-109X(14)70227-X. PubMed PMID: 25103301.
- WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. WHO
 Guidelines Approved by the Guidelines Review Committee. Geneva2011.
- 356 6. Zuspan FP. Problems encountered in the treatment of pregnancy-induced hypertension. A point 357 of view. American journal of obstetrics and gynecology. 1978;131(6):591-7. PubMed PMID: 686045.
- 358 7. Go Medicals Industries Pty Ltd. Innovative Products to improve common medical procedures.
- 359 <u>http://www.gomedicalcomau/products/infusion/springfusor-fct</u> Accessed September 25, 2017.

8. Easterling T, Hebert M, Bracken H, Darwish E, Ramadan MC, Shaarawy S, et al. A randomized
 trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with
 serial intravenous boluses versus a continuous intravenous infusion. BMC pregnancy and childbirth.
 2018;18(1):290. Epub 2018/07/07. doi: 10.1186/s12884-018-1919-6. PubMed PMID: 29976161; PubMed
 Central PMCID: PMCPMC6034206.

Mundle S, Regi A, Easterling T, Biswas B, Bracken H, Khedekar V, et al. Treatment approaches for
preeclampsia in low-resource settings: A randomized trial of the Springfusor pump for delivery of
magnesium sulfate. Pregnancy hypertension. 2012;2(1):32-8. doi: 10.1016/j.preghy.2011.09.002.
PubMed PMID: 26104987.

Freebairn R, Joynt GM, Lipman J, Bothma PA. A double-blind comparison of vecuronium
administered by the Springfusor infusion device to vecuronium by intermittent bolus injection in
critically ill adult patients. Anaesthesia and intensive care. 1994;22(5):580-5. PubMed PMID: 7818063.

- Murphy JF. Consort 2010 statement on randomised controlled trials. Ir Med J. 2010;103(5):132.
 Epub 2010/07/30. PubMed PMID: 20666080.
- 37412.Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for375eclampsia. The Cochrane database of systematic reviews. 2010;(12):CD000127. doi:
- 376 10.1002/14651858.CD000127.pub2. PubMed PMID: 21154341.
- 377 13. Pritchard JA. The use of the magnesium ion in the management of eclamptogenic toxemias.
 378 Surgery, gynecology & obstetrics. 1955;100(2):131-40. PubMed PMID: 13238166.
- 14. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations.
 The American journal of tropical medicine and hygiene. 2003;68 3:341-4.
- Friedmann PD, Mello D, Lonergan S, Bourgault C, O'Toole TP. Aversion to injection limits
 acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Subst Abus.
 2013;34(2):94-6. Epub 2013/04/13. doi: 10.1080/08897077.2012.763083. PubMed PMID: 23577900;
- 384 PubMed Central PMCID: PMCPMC4394196.
- Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a
 survey characterizing the perspectives of health care providers and US women 18-45 years old. Patient
 Prefer Adherence. 2019;13:351-61. Epub 2019/03/14. doi: 10.2147/PPA.S187120. PubMed PMID:
 30863023; PubMed Central PMCID: PMCPMC6391128.

389 17. Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication
 390 administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer

- Adherence. 2015;9:923-42. Epub 2015/07/15. doi: 10.2147/PPA.S87271. PubMed PMID: 26170642;
- 392PubMed Central PMCID: PMCPMC4494621.



Fig. 1. Consort diagram showing the participants flow

Fig.1 consort diagram



administration of the loading and maintenance doses of MgSO4

Fig. 2 Springfusor pump & FCT



Fig. 3 Showing participant with Springfusor pump with magnesium sulphate administered through a canula. The neck suspension string enables participants mobility without fear of dislodging the canula.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.16.23290038; this version posted May 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Fig. 3 Participants with Springfusor pump